Cybin Inc
AMEX:CYBN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/OCF
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Enterprise Value to Operating Cash Flow (EV/OCF) ratio compares a company`s total enterprise value to its operating cash flow. It shows how much investors are paying for each dollar of the company`s operating cash flow, including both equity and debt.
Valuation Scenarios
If EV/OCF returns to its Industry Average (10.4), the stock would be worth $-1.21 (123% downside from current price).
| Scenario | EV/OCF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -45 | $5.25 |
0%
|
| Industry Average | 10.4 | $-1.21 |
-123%
|
| Country Average | 11.9 | $-1.39 |
-127%
|
Forward EV/OCF
Today’s price vs future operating cash flow
Peer Comparison
| Market Cap | EV/OCF | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
C
|
Cybin Inc
AMEX:CYBN
|
4B USD | -45 | -41.5 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 51.3 | 40.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 23.2 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 15.2 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 21.1 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.2B CHF | 15.2 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 18.6 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 936 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 10.5 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 17.2 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 10.5 | 16.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 7.9 |
| Median | 11.9 |
| 70th Percentile | 19.5 |
| Max | 22 577.3 |
Other Multiples
Cybin Inc
Glance View
In the intricate world of biotechnology, Cybin Inc. emerges as a formidable player, navigating the uncharted waters of psychedelic therapeutics. Known for its innovative approach, Cybin is focused on revolutionizing mental health treatment through the research and development of psychedelic compounds. The company's ambition is to unlock the therapeutic potential of these substances, particularly psilocybin, the active component in magic mushrooms. By employing advanced drug delivery systems and conducting rigorous clinical trials, Cybin aims to optimize the effectiveness and safety of these compounds, addressing complex mental health issues such as depression, anxiety, and addiction. Cybin operates by transforming its groundbreaking research into viable commercial opportunities, thus fueling its revenue stream. The company's business model is primarily research and development-centric, relying on strategic collaborations and proprietary technological advancements to propel its clinical pipelines into the pharmaceutical marketplace. Revenue is generated through partnerships with academic institutions and contract research organizations, as well as through licensing agreements for their patented delivery systems. As Cybin continues to make strides in this nascent field, it positions itself not just as a company, but as a pioneer, boldly charting a new course in the crucial intersection of mental health and biotechnology.
